Regina C. Betz, Ofer Isakov, Maria-Teresa Romano, Laura N Uwakwe, L. Malki, Emily Warshauer, Noam Adir, Valeria Briskin, Michel Simon, Amy J. McMichael, Eli Sprecher, Alon Peled, Ofer Sarig, Marie-Claire Méchin, Ncoza C. Dlova, J. Mohamad, Andrea Gat, Tom Rabinowitz, M. Pavlovsky, Liat Samuelov, Noam Shomron, CARBILLET, Véronique, Tel Aviv Sourasky Medical Center [Te Aviv], Sackler Faculty of Medicine, Tel Aviv University (TAU), Institut für Genetik - Universität Bonn / Institute of Genetics - University of Bonn, Unité différenciation épidermique et auto-immunité rhumatoïde (UDEAR), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Wake Forest Baptist Medical Center, Schulich faculty of chemistry, Technion - Israel Institute of Technology [Haifa], University of KwaZulu-Natal [Durban, Afrique du Sud] (UKZN), Tel Aviv University [Tel Aviv], and University of KwaZulu-Natal (UKZN)
International audience; Background: Central centrifugal cicatricial alopecia (CCCA) is the most common form of scarring alopecia among women of African ancestry. The disease is occasionally observed to affect women in families in a manner that suggests an autosomal dominant trait and usually manifests clinically after intense hair grooming. We sought to determine whether there exists a genetic basis of CCCA and, if so, what it is. Methods: We used exome sequencing in a group of women with alopecia (discovery set), compared the results with those in a public repository, and applied other filtering criteria to identify candidate genes. We then performed direct sequencing to identify disease-associated DNA variations and RNA sequencing, protein modeling, immunofluorescence staining, immunoblotting, and an enzymatic assay to evaluate the consequences of potential etiologic mutations. We used a replication set that consisted of women with CCCA to confirm the data obtained with the discovery set. Results: In the discovery set, which included 16 patients, we identified one splice site and three heterozygous missense mutations in PADI3 in 5 patients (31%). (The approximate prevalence of the disease is up to 5.6%.) PADI3 encodes peptidyl arginine deiminase, type III (PADI3), an enzyme that post-translationally modifies other proteins that are essential to hair-shaft formation. All three CCCA-associated missense mutations in PADI3 affect highly conserved residues and are predicted to be pathogenic; protein modeling suggests that they result in protein misfolding. These mutations were found to result in reduced PADI3 expression, abnormal intracellular localization of the protein, and decreased enzymatic activity - findings that support their pathogenicity. Immunofluorescence staining showed decreased expression of PADI3 in biopsy samples of scalp skin obtained from patients with CCCA. We then directly sequenced PADI3 in an additional 42 patients (replication set) and observed genetic variants in 9 of them. A post hoc analysis of the combined data sets showed that the prevalence of PADI3 mutation was higher among patients with CCCA than in a control cohort of women of African ancestry (P = 0.002 by the chi-square test; P = 0.006 by Fisher's exact test; and after adjustment for relatedness of persons, P = 0.03 and P = 0.04, respectively). Conclusions: Mutations in PADI3, which encodes a protein that is essential to proper hair-shaft formation, were associated with CCCA. (Funded by the Ram Family Foundation and others.).